Grace Halsey

New evidence-based guidance for bowel prep considers patient preference and history and updates timing of prep regimen, dietary restrictions, and follow-up recommendations.

Overweight individuals in the highest dose group with weight loss at day 28 continued to lose weight at the 2-week follow-up, with metabolic changes mimicking ketogenic effects.

Posing an unparalleled threat of premature disease and death globally, the unchecked rise in overweight and obesity requires an urgent 5-year action plan, experts say.

Axsome Therapeutics reported that the FDA feedback supports the company's regulatory package for a sNDA for the dextromethorphan/bupropion combination.

CDC midseason data suggest low COVID-19 vaccine efficacy in adults aged 18 to 64 years, with somewhat better impact on those aged 65 years and older.

They are a Janus kinase (JAK)1/JAK2 inhibitor, a phosphodiesterase-4 inhibitor, and an investigational aryl hydrocarbon receptor agonist. Learn more about each.

Two official US vaccine planning meetings cancelled in February is an "unprecedented situation," said NFID medical director Robert Hopkins, Jr, MD.

The FDA has set a PDUFA target action date for October 13, 2025, according to Arcutis Biotherapeutics.

Safety findings from the phase 3 OUtMATCH trial were notable, including no adverse events for omlizumab vs 30.5% for OIT and epinephrine use for 0% vs 37.3%, respectively.

The investigational once-daily oral analgesic, a potent inhibitor of a novel target for neuropathic pain, achieved meaningful pain reduction vs placebo.

Participants (aged 6 to 17 years) receiving neffy vs standard treatments had fewer skin, gastrointestinal, and respiratory symptoms at 15, 5, and 5 minutes, respectively.

Shahriari, assistant clinical professor of dermatology at Yale University School of Medicine, says greater understanding of the condition has expanded the population for the diagnosis.

AAAAI 2025: Dupilumab was associated with a 56.9% reduction in IgE levels at 12 months and of 73.5% at 24 months, according to results presented at AAAAI 2025.

Although many women experience symptoms of perimenopause between ages 30 and 35, the majority do not seek medical attention for up to 2 decades, a new study reveals.

Up to 80% of atopic dermatitis is managed in primary care but some patients will need a higher level of care. Dr Mona Shahriari discusses factors that point to referral.

Not all atopic dermatitis requires treatment by a specialist, says this dermatologist, and she collaborates regularly with her primary care colleagues.

While the data on zonisamide efficacy for migraine in youths is preliminary, all study participants experienced a 66% reduction in headaches after 1 month of treatment.

A rural west Texas "undervaccinated" Mennonite community is the epicenter of the worst measles outbreak in the state in 30 years, the state health department reported.

Symbravo, compared with previous CGRP inhibitor therapy, achieved superior response across efficacy measures including pain freedom and improvements in QoL.

The proprietary combination of 2 neurostimulation modalities deployed simultaneously may enhance efficacy while reducing treatment time by 70%, the company said.

Comorbid conditions accrued at a rate 30% faster among adults with depression than in those without the disorder over a 7-year follow-up period.

Treatment of AD with dupilumab, compared with cyclosporine and methotrexate, was associated with significantly reduced risk of a wide range of CV outcomes at 1 year.

The outsized burden continues among Black men, a group with prostate cancer incidence rates 67% higher than those of White men and mortality rates more than twice as high.

Tips cover biologic agents and hepatitis B, 5-FU plus calcipotriene for AK, a triple treatment package for post-acne postinflammatory hyperpigmentation, and more.

The sudden appearance of "a black nail" can frighten a patient and should be investigated. Nail expert Boni Elewski, MD, shares 3 cases and the outcomes.

Susan C Taylor, MD, is internationally recognized for her expertise in dermatologic conditions in skin of color and spoke about avoiding photodamage at the Midwinter Clinical Derm Conference.

Established therapies for these common disorders don't always lead to optimal results; experts offer new evidence-based options that may help.

Systemic therapy for nail disorders, including biologics and JAK inhibitors, is gaining favor; learn more about early diagnosis and aggressive treatment from an expert.

From the revolutionary approval of dupilumab to the promise of potential disease modification with OX40 inhibitors, Golant provided a wide-ranging update of the treatment space.

How to treat lichenoid dermatoses, what to do when the Quant Gold is indeterminate, pocket-sized Wood lights, plus 9 more pearls from the experts.